Bingzong Li

Trials

Studies that name Bingzong Li as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov

• Early Ph1
  NCT07598578 · An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

  Second Affiliated Hospital of Soochow University · recruiting · Peripheral T-Cell Lymphoma Refractory · study chair
• Ph2
  NCT07002099 · Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

  Second Affiliated Hospital of Soochow University · recruiting · Lymphomas · principal investigator
• N/A
  NCT06289959 · Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL

  Second Affiliated Hospital of Soochow University · not yet recruiting · Lymphoma, Large B-Cell, Diffuse · study chair
• Ph1/Ph2
  NCT05857982 · Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

  Second Affiliated Hospital of Soochow University · unknown · Relapsed/Refractory Multiple Myeloma · principal investigator
• N/A
  NCT05690191 · Chidamide in Patients With Recurrent and Refractory Diffuse Large b

  Second Affiliated Hospital of Soochow University · unknown · Diffuse Large B-cell Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.